Almotriptan 12.5mg tablets

Almotriptan is a prescription medicine used to treat migraine attacks once they've started. It belongs to the triptan family of medicines, the same class as sumatriptan, rizatriptan, zolmitriptan, and the other commonly used migraine medicines. In the UK it was originally marketed under the brand name Almogran (made by Almirall), although that brand has been discontinued and the medicine is now widely available as generic almotriptan. It comes in one strength only: 12.5 mg tablets. Unlike sumatriptan and zolmitriptan, almotriptan is not available as a nasal spray or injection in the UK, so the tablet is the only option. It's used for acute treatment of migraine with or without aura.

This is the most useful question to address first, because the main reason a prescriber chooses almotriptan over its better-known cousins is usually tolerability. Almotriptan has a milder side effect profile than sumatriptan in particular. The classic "triptan sensations" (chest tightness, neck pressure, jaw tightening, tingling) tend to be less common and less intense with almotriptan, and the medicine causes less drowsiness, less nausea, and a lower rate of headache recurrence after initial response than sumatriptan in several head-to-head studies. The trade-off is that almotriptan has a slightly slower onset than rizatriptan and is only available as a tablet, with no nasal spray or injection form for faster-acting situations. Compared with rizatriptan, almotriptan also has the practical advantage of not interacting significantly with propranolol, which is the most commonly prescribed migraine preventive in the UK. Rizatriptan requires a dose reduction in anyone taking propranolol; almotriptan doesn't, which simplifies prescribing for patients on combined acute-and-preventive regimens. Patients who respond to almotriptan tend to stay on it long term precisely because side effects are less of a daily friction than with the older triptans.

The dose looks unusual because most other migraine medicines come in round-number strengths (50 mg, 100 mg, 10 mg). The 12.5 mg almotriptan dose reflects the medicine's pharmacology, specifically its unusually high oral bioavailability. Whereas sumatriptan tablets only deliver around 14 per cent of the swallowed dose into the bloodstream and rizatriptan around 45 per cent, almotriptan reaches about 70 per cent. That higher bioavailability means a smaller swallowed dose achieves the blood levels needed for clinical effect. So 12.5 mg of almotriptan does roughly the same job as 50 to 100 mg of sumatriptan, just with less medicine needing to enter the gut to get there. The higher bioavailability also makes almotriptan less affected by the slow stomach emptying that often happens during a migraine attack, which is one reason it tends to be more reliable than older oral triptans.

Migraine isn't a regular headache. During an attack, blood vessels in the head dilate, and a set of nerves around those vessels (the trigeminal nerves) release inflammatory chemicals that cause throbbing pain, nausea, sensitivity to light and sound, and the other classic migraine symptoms. Almotriptan works on receptors called 5-HT1B and 5-HT1D, which sit on those dilated vessels and on the nerve endings around them. Activating 5-HT1B receptors causes the dilated vessels to constrict back to their normal size. Activating 5-HT1D receptors stops the trigeminal nerves releasing the inflammatory chemicals that drive the pain. The result is that the migraine attack is interrupted at its source rather than just having the pain dulled. This is the same mechanism shared by all the triptans, which is why they all treat migraines but won't help tension headaches or other types of head pain.

As early as possible after the headache phase begins. This is one of the most consistent findings in migraine research: triptans work much better when taken at the first sign of head pain than once a migraine is fully established. Many people with regular migraines learn to recognise the earliest signals: a slight visual disturbance, a dull ache behind one eye, a strange stiffness in the neck, or a sense that "something's coming". Acting at that point can often abort the attack entirely. Waiting until you're vomiting and lying down in a dark room reduces the chance of a good response significantly. If you have an aura before your headache, the usual advice is to wait until the headache itself starts before taking almotriptan, because the aura phase doesn't respond to triptans and you don't want to use up a dose too early.

The standard adult dose is 12.5 mg, swallowed whole with water, as soon as the headache begins. There's no half-strength version, so 12.5 mg is the only single-tablet dose available. If the migraine comes back within 24 hours after an initial response, a second 12.5 mg tablet can be taken at least 2 hours after the first, up to a maximum of 25 mg (two tablets) in 24 hours. If the first dose has no effect at all, a second dose is unlikely to help, and continuing to dose for the same attack isn't recommended. Almotriptan is licensed for adults 18 and over in the UK and isn't generally used in adolescents, where Imigran nasal spray is the more commonly prescribed option.

Almotriptan typically starts to take effect within 30 minutes of swallowing the tablet, with peak effect at around 1.5 to 3 hours. About 60 to 70 per cent of people get meaningful pain relief within 2 hours of taking the standard 12.5 mg dose, and around 40 per cent are completely pain-free at 2 hours. Earlier dosing pushes those numbers up; waiting until the attack is fully established pushes them down. Almotriptan is slightly slower in onset than rizatriptan (which peaks at around 1 hour) but generally produces fewer side effects, which is one of the most consistent reasons it's chosen.

The general rule is to avoid taking a second dose for the same attack if the first dose has had no effect at all. If it partially worked or worked and then wore off, a second dose can help, but if the first attempt did nothing, more of the same is unlikely to help. Options at that point include adding a painkiller such as ibuprofen or naproxen, an anti-sickness medicine like metoclopramide (which also helps the gut absorb other medicines better), or waiting the attack out in a dark, quiet room with hydration. For future attacks, it's worth a conversation with your prescriber about whether another triptan might work better. Triptans are not interchangeable; many people who don't respond to one will respond to another, and it's reasonable to try several before concluding the class doesn't work for you. If almotriptan stopped working for you specifically because of side effects rather than lack of efficacy, that's worth discussing too, because the side effect profiles of the various triptans differ enough that another option may suit you better.

Almotriptan is generally one of the better-tolerated triptans, which is much of its appeal. The "triptan sensations" common to this class of medicine, including tingling, mild warmth or coolness, and a sense of pressure or tightness in the chest, throat, neck, or jaw, can still occur but tend to be milder than with sumatriptan. Other reported effects include drowsiness, dizziness, dry mouth, and mild nausea, all of which are also generally less common with almotriptan than with the older triptans. The chest tightness in particular tends to alarm people the first time they experience it, because the natural assumption is that it's something cardiac. In healthy people without heart disease this sensation isn't dangerous and reflects the medicine's action on blood vessels and smooth muscle, and it usually settles within 30 minutes to an hour. That said, real cardiac chest pain can occur in someone with undiagnosed heart disease who takes a triptan, so the distinction matters. If the chest sensation is severe, prolonged, crushing, associated with breathlessness, or radiating down the arm, that needs urgent assessment rather than being assumed to be a "triptan sensation".

A few interactions matter. Almotriptan should not be taken with monoamine oxidase inhibitor antidepressants (MAOIs) or within two weeks of stopping one, because the combination can cause dangerous rises in blood pressure and serotonin syndrome. It shouldn't be taken with another triptan or with ergotamine-type migraine medicines on the same day, because the vasoconstriction effects can add up. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), such as sertraline, citalopram, or venlafaxine, carry a small theoretical risk of serotonin syndrome when combined with triptans, though in practice this is rare. Strong inhibitors of the liver enzyme CYP3A4 (such as the antifungals ketoconazole and itraconazole, and HIV medicines like ritonavir) can raise almotriptan blood levels, although the clinical effect is usually modest. One useful point: almotriptan has no significant interaction with propranolol, which is the most commonly prescribed migraine preventive, so the dose doesn't need adjusting if you're on combined acute-and-preventive treatment. Always tell prescribers what else you're taking, including over-the-counter medicines and herbal remedies (St John's Wort is particularly relevant for triptans).

Yes, in most cases. Almotriptan causes blood vessel constriction including in the coronary arteries that supply the heart muscle. In someone with healthy arteries this is harmless and transient, but in someone whose coronary arteries are already narrowed by atherosclerosis, even a small additional constriction can reduce blood flow to the heart enough to cause angina or, in rare cases, a heart attack. Almotriptan is therefore contraindicated in established ischaemic heart disease, previous heart attack, coronary artery vasospasm (Prinzmetal's angina), uncontrolled high blood pressure, previous stroke, and peripheral vascular disease. It's also used with caution in people who don't have known heart disease but who carry significant cardiovascular risk factors (men over 40, postmenopausal women, smokers, diabetes, raised cholesterol, family history of premature heart disease). In those situations a cardiovascular assessment before starting any triptan is often recommended. The cardiovascular cautions apply to almotriptan just as they apply to sumatriptan and rizatriptan, despite almotriptan's gentler general side effect profile.

The safety data for almotriptan in pregnancy is limited compared with sumatriptan, which has been on the market longer and has a much larger accumulated registry of pregnancy outcomes. What evidence exists doesn't show clear harm, but most clinicians prefer sumatriptan in pregnancy where a triptan is needed, simply because the safety database is so much bigger. If you're pregnant or planning a pregnancy and currently on almotriptan, the conversation is worth having with your GP rather than self-managing. In breastfeeding, almotriptan passes into breast milk in small amounts, and the standard advice is to avoid breastfeeding for 24 hours after a dose. Some recent guidance takes a more relaxed view, but the 24-hour interval remains the conservative approach. Many women express and discard breast milk during that window to maintain supply.

This is one of the most important things to understand about triptans, because the danger isn't using them, it's using them too often. Medication overuse headache (MOH) is a surprisingly common problem in which the body's response to frequent triptan use becomes paradoxical: the medicines that were helping start producing rebound headaches, which then prompt more medicine use, in a cycle that can become entrenched. The current threshold is taking a triptan on more than 10 days a month, on average, for three or more months. Above that level, the risk of MOH rises significantly. If you find yourself reaching for almotriptan 10 or more days a month, that's a strong signal that the conversation needs to shift from acute treatment to preventive treatment, a different category of medicine designed to reduce how often migraines happen in the first place. Treatment of medication overuse headache involves stopping the overused medicine for a period to allow the headache pattern to reset, often with specialist guidance, and the headache pattern usually settles into a better baseline once that's been done.

No, almotriptan is an acute treatment: it interrupts a migraine once it's started. It doesn't change how often migraines happen, how severe they are, or any of the underlying drivers of the condition. Prevention is a separate category of treatment worth discussing with a clinician if your migraines are frequent (more than four a month is a common threshold), severely disabling, or not well controlled with acute treatment. Preventive options include beta-blockers (propranolol, which doesn't interact problematically with almotriptan, unlike with rizatriptan), topiramate, amitriptyline, candesartan, and the newer injected CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab). Botulinum toxin injections are also licensed for chronic migraine prevention. Beyond the prevention question, several features call for prompt medical review: a first-ever severe headache, particularly one that comes on suddenly or feels different from anything you've had before (which can be a warning of meningitis or subarachnoid haemorrhage and should be treated as an emergency); migraine lasting more than 72 hours without responding to treatment ("status migrainosus"); new neurological symptoms that don't fit your usual aura pattern; headaches that wake you from sleep, consistently get worse over weeks, or come with weight loss, fever, or other systemic symptoms. A clinical review is also worth having if your migraines are happening often, if almotriptan isn't enough, if you're using it on more than 10 days a month, or if you've never had a formal migraine diagnosis. Modern migraine care has changed considerably with the arrival of CGRP-targeting treatments, and many people who've been managing on triptans alone for years find that a proper review opens up better options.